<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95573">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01652456</url>
  </required_header>
  <id_info>
    <org_study_id>ALTAKRA - 1205</org_study_id>
    <nct_id>NCT01652456</nct_id>
  </id_info>
  <brief_title>Alcohol and Tobacco Consumption in Patients With Head and Neck Cancer : Interest of an Addiction Support</brief_title>
  <official_title>Alcohol and TObacco Consumption in Patients With Head and Neck Cancer : Interest of an Addiction Support</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <authority>France: Committee for the Protection of Personnes</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, interventional, randomized study for preventive and therapeutic
      strategies for patients with head and neck or Lung cancer; contribution of an addiction
      support
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>systematic addiction consultation</measure>
    <time_frame>12 months after diagnosis</time_frame>
    <safety_issue>No</safety_issue>
    <description>difference between abstinence in group A and abstinence in group B</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>24 months after diagnosis</time_frame>
    <safety_issue>No</safety_issue>
    <description>median time between date of inclusion and date of first progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>24 months after survival</time_frame>
    <safety_issue>No</safety_issue>
    <description>median time between date of inclusion and date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>alcohol and tobacco consumption</measure>
    <time_frame>baseline, 3 months, 6 months and 12 months after diagnosis</time_frame>
    <safety_issue>No</safety_issue>
    <description>frequency of tobacco and alcohol consumption questionnaire : Fagerström, Alcohol Use Disorders Identification Test (AUDIT), Cut Down Annoyed Guilty Eye-Opener (CAGE-DETA), Cannabis abuse screening test (CAST), M.I.N.I.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>alcohol + tobacco withdrawal and addiction support</measure>
    <time_frame>12 months after diagnosis</time_frame>
    <safety_issue>No</safety_issue>
    <description>difference between abstinence of group A and abstinence group B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>addiction follow up</measure>
    <time_frame>24 months after diagnosis</time_frame>
    <safety_issue>No</safety_issue>
    <description>percentage of patient with a first addiction consultation, and willing to have a long term follow up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Addiction support</intervention_name>
    <description>one consultation with an addiction specialist</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  first head and neck or lung cancer

          -  first support

          -  18 ≤ age ≤ 60

          -  lives in Lille Metropolis

          -  having an addiction to alcohol and tobacco

          -  covered by health insurance

          -  signed informed consent

        Exclusion Criteria:

          -  prior cancer

          -  mesothelioma and oesophageal cancer

          -  unable to undergo trail medical follow up (geographical, social and psychological
             reasons)

          -  pregnant or nursing woman

          -  patient under guardianship
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corinne VANNIMENUS, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier Régional et Universitaire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Corinne VANNIMENUS, MD</last_name>
    <phone>+33 (0)3.20.44.66.55</phone>
    <email>corinne.vannimenus@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oscar Lambret Center</name>
      <address>
        <city>Lille</city>
        <zip>59 020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Louis LEFEBVRE, MD PhD</last_name>
      <phone>+33 (0)3.20.29.59.20</phone>
      <email>jl-lefebvre@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Louis LEFEBVRE, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie EL BEDOUI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean TON VAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yann MALLET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gauthier LEFEBVRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marian DEGARDIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric DANSIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alain JOVENIAUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional et Universitaire - Hopital CALMETTE</name>
      <address>
        <city>Lille</city>
        <zip>59 037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Corinne VANNIMENUS, MD</last_name>
      <phone>+33 (0)3.20.44.66.55</phone>
      <email>corinne.vannimenus@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Arnaud SCHERPEREEL, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Corinne VANNIMENUS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier COTTENCIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin ROLLAND, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional et Universitaire - Hopital HURIEZ</name>
      <address>
        <city>Lille</city>
        <zip>59 037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Corinne VANNIMENUS, MD</last_name>
      <phone>+33 (0)3.20.44.66.55</phone>
      <email>corinne.vannimenus@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Dominique CHEVALIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier PASQUESOONE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geoffrey MORTUAIRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier COTTENCIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin ROLLAND, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <lastchanged_date>July 30, 2012</lastchanged_date>
  <firstreceived_date>July 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>addiction support</keyword>
  <keyword>addiction specialist</keyword>
  <keyword>lung cancer</keyword>
  <keyword>head and neck cancer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Behavior, Addictive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
